ZA965026B - Doping of crystalline substrates - Google Patents

Doping of crystalline substrates

Info

Publication number
ZA965026B
ZA965026B ZA965026A ZA965026A ZA965026B ZA 965026 B ZA965026 B ZA 965026B ZA 965026 A ZA965026 A ZA 965026A ZA 965026 A ZA965026 A ZA 965026A ZA 965026 B ZA965026 B ZA 965026B
Authority
ZA
South Africa
Prior art keywords
doping
crystalline substrates
crystalline
substrates
Prior art date
Application number
ZA965026A
Inventor
Johan Frans Prins
Original Assignee
De Beers Ind Diamond
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by De Beers Ind Diamond filed Critical De Beers Ind Diamond
Priority to ZA965026A priority Critical patent/ZA965026B/en
Publication of ZA965026B publication Critical patent/ZA965026B/en

Links

ZA965026A 1995-06-23 1996-06-13 Doping of crystalline substrates ZA965026B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
ZA965026A ZA965026B (en) 1995-06-23 1996-06-13 Doping of crystalline substrates

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ZA955217 1995-06-23
ZA965026A ZA965026B (en) 1995-06-23 1996-06-13 Doping of crystalline substrates

Publications (1)

Publication Number Publication Date
ZA965026B true ZA965026B (en) 1997-01-23

Family

ID=27142673

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA965026A ZA965026B (en) 1995-06-23 1996-06-13 Doping of crystalline substrates

Country Status (1)

Country Link
ZA (1) ZA965026B (en)

Similar Documents

Publication Publication Date Title
GB2306470B (en) Reactive liquid crystalline compound
HK1023125A1 (en) Crystalline form of 4-Ä5-methyl-3-phenylisoxazol-4-ylÜbenzenesulfonamide
SG71006A1 (en) Fabrication process of soi substrate
AU6772996A (en) 2-acylaminopropanamides as growth hormone secretagogues
PL321590A1 (en) Compounds capable to cause liberation of the growth hormone
PL327438A1 (en) Transgenous plant of altered ageing characteristic
GB9511935D0 (en) Novel compound
ZA969753B (en) Crystalline hydrochloride of (r)-(-)-2-än-4-(1,1-dioxido-3-oxo-2,3-dihydrobenzhisothiazol-2-yl)-aminomethylü-chroman
IL141433A0 (en) Crystalline forms of eto2c-ch2- (r) cgl-aze-pab-oh
AU6724496A (en) 2-acylaminopropanamines as growth hormone secretagogues
ZA965234B (en) Bioavailable crystalline form of cefuroxime exetil
EP0750058A3 (en) Doping of crystalline substrates
AU4953796A (en) Dipeptide compounds having ahpba structure
AU7020296A (en) Timepiece
EP0735125A3 (en) Liquid crystalline allenes
EP0733725A3 (en) Growth of silicon single crystal
PL337612A1 (en) Crystalline form of roxyfiban
AU4453396A (en) Growth factor analogs
ZA965026B (en) Doping of crystalline substrates
AU6127096A (en) Solar geo-stellar planisphere
GB2326648B (en) Growth method of polycrystal silicon film
AU4941900A (en) Doping of crystalline substrates
AU4659196A (en) Methods of inhibiting growth hormone effects
PL325602A1 (en) Alternative crystalline form of thazophenelone
AU4649996A (en) Quranic watch